Cognate BioServices, a leading contract development and manufacturing organization (CDMO) specialized in cell and cell-mediated gene therapy products and Cobra Biologics, a leading CDMO specialized in providing manufacturing services for plasmid DNA and viral vector, today announced that they have entered into a definitive agreement in which Cognate will acquire all of the outstanding share capital of Cobra. Existing Cognate investor EW Healthcare Partners led the financing for the acquisition. Source: Cognate Press release 4/11/2019